ArticleInternational journal of general medicine2025
Potential Diagnostic Value of Circular RNA hsa_circ_0008882 in Rheumatic Valvular Heart Disease.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To investigate the involvement of circular RNA (circRNA) in the pathogenesis of rheumatic valvular heart disease (RVHD) and its potential use as a diagnostic biomarker. Methods: Three differentially expressed circRNAs in RVHD were selected. Four pairs of RVHD valve tissues and non-RVHD valve tissues were verified. Plasma samples from 41 RVHD patients and 39 healthy controls were analyzed to investigate the relationship between hsa_circ_0008882 expression levels and clinical-pathological characteristics in RVHD patients, evaluating its diagnostic value for RVHD. Additional plasma samples from 47 RVHD patients and 30 controls, along with 38 valve tissues, were collected to validate the expression of downstream target genes CAMTA2 and APLN. LASSO regression combined with multivariate logistic regression analysis was employed to identify independent risk factors. The interaction between hsa_circ_0008882 and hsa-miR-4739 was validated through dual luciferase reporter assays. Results: The expression of hsa_circ_0008882 was significantly upregulated in both plasma and valve tissue samples from RVHD patients. Plasma hsa_circ_0008882 demonstrated moderate discriminatory ability for RVHD, with an AUC of 0.707 (95% CI: 0.591-0.823), a sensitivity of 58.5%, and a specificity of 82.1% at the optimal cutoff value. Its expression level showed significant positive correlations with multivalvular heart disease, left atrial diameter, and pulmonary artery systolic pressure. After LASSO regression screening, multivariate analysis confirmed hsa_circ_0008882 as an independent risk factor for RVHD (OR = 3.73, 95% CI: 1.75-7.95). Mechanistic exploration revealed that hsa_circ_0008882 directly binds to hsa-miR-4739, and its potential target genes CAMTA2 and APLN were both upregulated in plasma and tissue samples from RVHD patients. Conclusion: Hsa_circ_0008882 plays an essential role in RVHD, and its plasma expression levels may serve as a potential auxiliary diagnostic indicator for RVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.